Founded in 2008, Beijing Health Guard Biotechnology, Inc. is a high-tech enterprise that is dedicated to the R&D and commercialization of innovative vaccines. As a top-tier player in the development of HPV vaccines in China, the Company boasts the most comprehensive HPV vaccine franchise worldwide that comprises a Trivalent, a Nonavalent and a 15-valent HPV vaccine. The Company is transitioning from a biotech concern to a biopharma company.

The Company has completed interim analysis in the phase Ⅲ efficacy trial of the Trivalent HPV on the disease endpoint (CIN2+) in August 2024, with positive data readout. The Company has had positive data readout from interim analysis in the phase Ⅲ efficacy trial in females in China of the Nonavalent HPV on the virological endpoint (PI12) in February 2025, too. Moreover, the Nonavalent HPV is the only homegrown HPV vaccine that is under clinical development overseas, with positive data readout from the first analysis on the primary endpoint in the phase Ⅲ trial in Indonesia concluded in January 2025. The Nonavalent HPV is also the first homegrown HPV vaccine candidate that has entered a phase Ⅲ efficacy study in males.

Currently, the Company has built an EU and China GMP-compliant pilot plant in Beijing, and is also constructing a manufacturing facility in Kunming in accordance with the GMP requirements of China, the EU and the WHO.

Since its inception, the Company has been certified as, among others, a High and New Technology Enterprise (HNTE) and a Beijing Specialized and Special New SMES.

The Company started to list on the Beijing Stock Exchange in March 2023 as the first innovative biotech start-up under the fourth set of listing standards since the opening of the Beijing Stock Exchange. Shares of the Company are trading under the ticker Health Guard and stock code 920575.

The Company values collaboration opportunities with industry peers. In 2019, the Company and Liaoning Chengda Biotechnology Co., Ltd. entered into a collaboration agreement on the development and commercialization of the 15-valent HPV vaccine candidate. The Company will also actively respond to the Global Strategy to Accelerate the Elimination of Cervical Cancer launched by the WHO by working with global partners to make its effective and quality vaccines more accessible, thereby helping relieve the world from vaccine-preventable infectious diseases!